The company is building a U.S.-based chemistry contract research organization (CRO) that brings expert chemists, AI, and robotics together to make and test the molecules research teams need. Its ambition is to make discovery compound: experimental data helps train better AI, better AI powers more capable labs, and scientists gain the capacity to test more ideas.

Warp's funding round was led by Lightspeed, with participation from Premji Invest, Mayfield, IVP, Lux, Conviction, Menlo Ventures, 01 Advisors, Standard, Lowercarbon Capital, Gigascale Capital, Angular Ventures, Scribble Ventures, Uncork Capital, Innovation Endeavors, Matter VP, Zero Shot Fund, SignalFire and Moxxie Ventures.

Angel investors include Brian Armstrong (Coinbase CEO), Mike Krieger (Anthropic Labs co-lead, Instagram co-founder), Milan Kovac (former Tesla Robotics VP), Ion Stoica (Databricks co-founder), Fidji Simo (former OpenAI AGI Deployment CEO), Brendan Foody (Mercor CEO), Mark Chen (OpenAI Chief Research Officer), Sarah Friar (OpenAI CFO), Kate Rouch (former OpenAI and Coinbase CMO), Lulu Meservey (Rostra CEO), Deepak Pathak (Skild CEO), Dylan Field (Figma CEO), and Lachy Groom (Physical Intelligence cofounder and COO).

Warp Sciences is building scientific infrastructure in the U.S. to help the world discover new medicines faster. It brings AI, robotics, and life sciences together in labs built for increasing automation, designed to run and learn from experiments so each cycle can improve the next. Warp has no proprietary drug pipeline. It builds the infrastructure for the research teams discovering new medicines. Its founders, Kevin Weil, DJ Patil, Sol Reisberg and Mano Paluri, bring experience from OpenAI, Terremoto Biosciences, Meta, Devoted Health and the White House.